Sign in

Bernard Kadosh

@bernardkadosh.bsky.social
348 followers 132 following 49 posts

Heart Failure and Transplant Cardiologist @NYU | Director, Cardiogenic Shock and VAD Program | APD, AHFTC Fellowship | Opinions are mine and not advice. Ready, able, and hemodynamically stable.

PostsRepliesMedia
Bernard Kadosh @bernardkadosh.bsky.social · 11/04/2026
🫀The lactate cleared, but your patient is still dying. Two SCAI presidents. One big question. Join Drs. Srihari Naidu & Sunil Rao as they debate: 💥 Quality Outcome Measures in Shock Register: nyulmc.org/heartfailurecme #HFx #CardiogenicShock #Cardiology #HeartFailure
010
Bernard Kadosh @bernardkadosh.bsky.social · 03/04/2026
Calling all🫀AHFTC and purveyors of #critcarecards Now that #ACC26 is over, come spend a weekend in NYC at the #1 cardiac hospital to learn about what's new and exciting #CardiogenicShock #Transplant #LVAD #TAH and more! ONE month away. ✍️Register now: nyulmc.org/heartfailurecme #HeartFailure
000
Bernard Kadosh @bernardkadosh.bsky.social · 15/12/2025
💯
020
Bernard Kadosh @bernardkadosh.bsky.social · 30/11/2025
Just because you can, doesn’t mean you should
000
Bernard Kadosh @bernardkadosh.bsky.social · 07/09/2025
Check out our editorial wherein my colleague Arushi Singh and I opine on the impact of obesity on heart #transplant outcomes. All hail #dadjokes as effective forms of communication. Article by D Kim and J Kobashigawa: doi.org/10.1016/j.he... Our Editorial: www.jhltonline.org/article/S105...
230
Bernard Kadosh @bernardkadosh.bsky.social · 15/04/2025
#ISHLT President Elect Josef Stehlik joins us at NYU for a perspective on🫀 #transplant Register now! bit.ly/NYUAHF2025 #MedEd #CardioEd #CardioSky #Cardiology #HeartFailure #ISHLT2025
042
Bernard Kadosh @bernardkadosh.bsky.social · 06/04/2025
🫀AHFTC and CCC folks come spend a weekend in NYC with some of the nation's best talking shop about all things #CardiogenicShock #Transplant #LVAD #TAH and more! ONE month away⌚️ Register now: bit.ly/NYUAHF25 #ACC25 #ISHLT2025 #Cardiology #CardioSky
253
Bernard Kadosh @bernardkadosh.bsky.social · 30/03/2025
High winds and truth bombs 💣 in Chicago at #ACC25 ☝️There is nothing “routine”about #CardiogenicShock ✌️Hemodynamics are the closest thing we have to truth in this world 👊Rules are made to be broken. Embrace complexity! @allisondupont.bsky.social @sarasvallabhmd.bsky.social
130
Bernard Kadosh @bernardkadosh.bsky.social · 30/03/2025
MCS: Which Device For Which Patient? Join me and an esteemed panel as we address some of your most 🔥 burning questions 🔥 and I share my philosophy on treating #CardiogenicShock 🧐 🤔 🤨 @allisondupont.bsky.social #ACC25 #cardiosky
033
Bernard Kadosh @bernardkadosh.bsky.social · 19/03/2025
📢Check out this issue of #JHLT wherein the crackerjack team At NYU highlights a gap in the current 🫀 allocation system. Anyone who has cared for a young patient with CAV knows this pain. t.co/Slbb4jLT6h
t.co
https://www.jhltonline.org/article/S1053-2498(24)01964-8/abstract
001
Bernard Kadosh @bernardkadosh.bsky.social · 12/02/2025
We are and already do. This trial created a permission structure to do the easiest thing for patients in complex situations. Not saying it’s always wrong, but binary decision making in shock leads to many unintended consequences. This is why we use shock teams to think of all possible futures.
110
Bernard Kadosh @bernardkadosh.bsky.social · 26/12/2024
Ask me about the time we found a part of one sticking through the right ventricle 🏹
000
Bernard Kadosh @bernardkadosh.bsky.social · 26/12/2024
Now this is a curve that says, “seemed like a good idea at the time…” #CardioSky #MedSky
1102
Bernard Kadosh @bernardkadosh.bsky.social · 21/12/2024
000
Bernard Kadosh @bernardkadosh.bsky.social · 18/12/2024
😂
000
Bernard Kadosh @bernardkadosh.bsky.social · 17/12/2024
Very proud of our team @nyulangonepccsm.bsky.social Making science fiction a new reality for patients with no other options. #Transplant #HealthEquity
051
Bernard Kadosh @bernardkadosh.bsky.social · 11/12/2024
👀 #CAV patients listed for #HeartTransplant face higher mortality than others at the same status. Status 4 = Status 3 Status 3 = Status 2 Guess we need to get our #OPTN priorities straight 🥁 www.sciencedirect.com/science/arti... #CardioSky #MedSky #TransplantEquity #HealthEquity
010
Bernard Kadosh @bernardkadosh.bsky.social · 09/12/2024
Would definitely be helpful!
000
Bernard Kadosh @bernardkadosh.bsky.social · 09/12/2024
Totally agree. The obsession over EF has hamstrung research efforts and clinical progress.
030
Bernard Kadosh @bernardkadosh.bsky.social · 09/12/2024
Amen
010
Bernard Kadosh @bernardkadosh.bsky.social · 09/12/2024
Otherwise other afterload reducers would be just as effective in HFrEF and that is just not the case (prazosin, amlodipine, metoprolol tartrate)
120
Bernard Kadosh @bernardkadosh.bsky.social · 09/12/2024
Agree, but more than that, EF is an artifact of LV dilatation; a function of a specific type of cardiomyopathy. GDMT works independently of afterload reduction by reducing beta receptor downregulation and preventing neurohormonal pathways to fibrosis. HFpEF pathology is completely different
120
Bernard Kadosh @bernardkadosh.bsky.social · 09/12/2024
So you’re selecting a treatment group that can tolerate SGLT2i that had a high rate of discontinuation for hypotension in the trials.
010
Bernard Kadosh @bernardkadosh.bsky.social · 09/12/2024
Skeptical of these results for a few reasons. The HFpEF trials of late benefit from enrollment of EF down to 40% which we know includes a HFrEF phenotype that responds to GDMT. Propensity matching in this group is frought. Sick amyloids can barely tolerate any meds due to dysautonomia.
210
Bernard Kadosh @bernardkadosh.bsky.social · 09/12/2024
Quick comment on my end. The app is great, but reporting the % size is problematic. We insist that the PHM RATIO is reported to avoid communication errors between team members with a misplaced or missing minus sign.
120
Reposted by Bernard Kadosh
Parham Eshtehardi MD @cardioobdoc.bsky.social · 08/12/2024
Mechanical Circulatory Support for Acute MI Cardiogenic Shock: Review & Recent Updates #CardioSky #MedSky www.jcvaonline.com/article/S105...
jcvaonline.com
Mechanical Circulatory Support for Acute Myocardial Infarction Cardiogenic Shock: Review and Recent Updates
Cardiogenic shock (CS) in acute myocardial infarction (AMI) is a life-threatening syndrome characterized by systemic hypoperfusion, which can quickly progress to multiorgan failure and death. Various devices and configurations of mechanical circulatory support (MCS) exist to support patients, each with unique pathophysiological characteristics. The Intra-aortic balloon pump (IABP) can improve coronary perfusion, decrease afterload, and indirectly augment cardiac output. TandemHeart, a percutaneous ventricular assist device (pVAD), can decrease left ventricular preload and directly augment cardiac output.
1114
Bernard Kadosh @bernardkadosh.bsky.social · 07/12/2024
I don’t yet have an avenue to help but I’ll be happy to speak with them if they need advice
100
Bernard Kadosh @bernardkadosh.bsky.social · 06/12/2024
Not the best level of evidence but this is consistent with my clinic experience using Entresto in ESRD patients. Have managed to get some recovered EFs to kidney transplant alone! www.ahajournals.org/doi/10.1161/...
ahajournals.org
Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease | Journal of the American Heart Association
010
Reposted by Bernard Kadosh
John Dodson MD @drdodson.bsky.social · 04/12/2024
So proud of mentee Dr. Sidhu who just matched at NYU for cardiology fellowship. Her future is bright - and we are lucky to have her. #CardioSky #Match2024
061
Bernard Kadosh @bernardkadosh.bsky.social · 04/12/2024
Really excellent state of the art review on the topic of withdrawal of GDMT www.jacc.org/doi/10.1016/... #cardiosky #medsky
jacc.org
Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction:
031
Bernard Kadosh @bernardkadosh.bsky.social · 04/12/2024
The patients you run into trouble with are usually diabetics with RTA. Sometimes the chronic CKD patients do this too, but I’m comfortable starting GDMT even with GFR in the 20-30 range. The renal function can improve over time, especially if you pay attention to volume status.
030
Bernard Kadosh @bernardkadosh.bsky.social · 04/12/2024
My threshold is much higher. I don’t discontinue unless the K is over 5.8 or so. Much of the time the patient just needs to hydrate a little and repeat the labs.
030
Bernard Kadosh @bernardkadosh.bsky.social · 04/12/2024
It’s a happy coincidence that both Entresto and SGLT2i mitigate hyperkalemia. I can count on 1 hand the amount of times I had to use a K binder for patients on full GDMT in the last 2 years. Useful to have, usually not necessary. #cardiosky #medsky
380
Reposted by Bernard Kadosh
Alex Truesdell @agtruesdell.bsky.social · 04/12/2024
scai.org/short-term-m...
scai.org
Short-Term Mechanical Circulatory Support for Cardiogenic Shock | SCAI
111
Bernard Kadosh @bernardkadosh.bsky.social · 04/12/2024
Awesome. Thank you!
010
Reposted by Bernard Kadosh
Harriette Van Spall MD MPH 🇨🇦 @hvanspall.bsky.social · 03/12/2024
Tobacco generates revenue and kills This #AHA policy statement reviews rates of use and health effects of #smokeless #tobacco & #nicotine products and #publichealth / #policy approaches to ending tobacco and nicotine addiction. buff.ly/3ZD7ON2
042
Reposted by Bernard Kadosh
Allen Amorn MD @allenamornmd.bsky.social · 03/12/2024
Great one pager for helping determine VT vs SVT with abberancy for tele and EKGs. #MedSky look like a rockstar on rounds if you can explain to your team these WCTs. #CardioSky. #FOAMed #MedEd
073
Reposted by Bernard Kadosh
EchoPro @echopro.bsky.social · 03/12/2024
I first heard about this in 1996 so now I’m starting to think the wearable patch transducer is just an elaborate game of "Are We There Yet? " #echofirst #cardiosky #medsky www.nibib.nih.gov/news-events/...
nibib.nih.gov
A stretchable, wearable patch for cardiac ultrasound
After years of research, an NIH-funded team has developed a wearable cardiac ultrasound imager that can non-invasively capture real-time images of the human heart. The prototype patch, which is about ...
082
Bernard Kadosh @bernardkadosh.bsky.social · 03/12/2024
Bizarre. What was the impetus for such a trial?
120
Bernard Kadosh @bernardkadosh.bsky.social · 03/12/2024
Link not working
100
Reposted by Bernard Kadosh
Kardioklick @kardioklick.bsky.social · 02/12/2024
More evidence that we may need to include CMR into our LV-thrombus search and exclude algorithms… disappointing that contrast doesn’t help. #echofirst #whycmr
243
Bernard Kadosh @bernardkadosh.bsky.social · 02/12/2024
Anyone with a new cardiomyopathy deserves at least one MRI. I think what this is telling us is that higher risk patients (those with poor apical wall motion) should have the MRI before we say there is no thrombus. But it also probably means that you need the MRI to decide whether to stop AC.
110
Bernard Kadosh @bernardkadosh.bsky.social · 01/12/2024
“Recovery in the HFrecEF group was temporary in most cases, with 50% of patients experiencing a decline in LVEF to <50% within 3.5 [interquartile range 2.4-4.9] years after the day of recovery.” Talk about single center data. Point taken about burdensome cost, but usually not worth it IMO.
100
Bernard Kadosh @bernardkadosh.bsky.social · 01/12/2024
To me, that is a staggering proportion of patients to recur with a disease that kills 50% within 5 years of diagnosis. The curves split within 8 weeks.
110
Bernard Kadosh @bernardkadosh.bsky.social · 01/12/2024
Yes. www.thelancet.com/article/S014... At least in DCM patients, 44% recurred within 6 months of withdrawal of GDMT.
thelancet.com
Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial
Many patients deemed to have recovered from dilated cardiomyopathy will relapse following treatment withdrawal. Until robust predictors of relapse are defined, treatment should continue indefinitely.
120
Reposted by Bernard Kadosh
Lars Mølgaard Saxhaug @load-dependent.eurosky.social · 30/11/2024
@andishahu.bsky.social has created a feed for Critical Care Cardiology! Use #cccsky for any post that is relevant, you can even comment with the tag to get it to the feed. #emimcc #cardiosky bsky.app/profile/did:...
42011
Bernard Kadosh @bernardkadosh.bsky.social · 27/11/2024
Consensus documents have been pushing Heart Failure with Improved EF (HFimpEF), which is fine. My personal mishigas is that categorical definitions based on EF are problematic generally. But it’s the world we live in 🤷🏻‍♂️
240
Bernard Kadosh @bernardkadosh.bsky.social · 27/11/2024
Yeah, I think that’s a special case in terms of risk of recurrence. There’s also the issue of chicken/egg since many of these RVR patients have underlying cardiomyopathies. All of that aside…still not HFpEF.
120
Bernard Kadosh @bernardkadosh.bsky.social · 27/11/2024
Bane of my existence
020
Bernard Kadosh @bernardkadosh.bsky.social · 27/11/2024
🚨PSA: Patients who recover their EF on GDMT don’t transform into HFpEF. They remain cardiomyopathy patients who are at risk of recrudescence. Keep them on GDMT and keep nonsense out of the chart. Happy Thanksgiving! #CardioSky #MedSky
6273